MEO-DOTA-NCS | 360045-93-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: MEO-DOTA-NCS
• 英文别名: 1-[(2-methoxy-5-isothiocyanatophenyl)-carboxymethyl]-4,7,10-triscarboxy-methyl-1,4,7,10-tetraazacyclododecane；α-(5-isothiocyanato-2-methoxyphenyl)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid；α-[(2-methoxy-5-isothiocyanatophenyl)-1,4,7,10-tetraazacyclododecane]-1,4,7,10-tetraacetic acid；2-(5-Isothiocyanato-2-methoxyphenyl)-2-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetic acid
• CAS: 360045-93-8
• 化学式: C₂₄H₃₃N₅O₉S
• 分子量: 567.62
• InChiKey: UPMSDWGVIHUJDU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -7.5
• 重原子数：
  39
• 可旋转键数：
  11
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  216
• 氢给体数：
  4
• 氢受体数：
  15

反应信息

• 作为反应物：
  描述：

  MEO-DOTA-NCS 、 YEVHHQKLVFF 在 sodium hydroxide 作用下， 以 水 为溶剂， 反应 16.0h， 生成 MeO-DOTA-β-amyloid conjugate
  参考文献：
  名称：

  [EN] PROTEIN AND POLYMER CONJUGATES AS CHELANTS WITH ENHANCED BLOOD RETENTION
  [FR] CHELATEURS A RETENTION SANGUINE AMELIOREE

  摘要：

  公开号：

  WO2005049096A3

文献信息

• Albumin fusion proteins
  申请人：HUMAN GENOME SCIENCES, INC.

  公开号：EP1997829A1

  公开（公告）日：2008-12-03

  The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention. The fusion protein may comprise a hybrid (human serum albumin)/Kex2 leader sequence followed by a mature albumin fused to the N-terminus of mature interferon alpha-2b.

  本发明包括白蛋白融合蛋白。本发明还包括编码本发明白蛋白融合蛋白的核酸分子、含有这些核酸的载体、用这些核酸载体转化的宿主细胞，以及制造本发明白蛋白融合蛋白和使用这些核酸、载体和/或宿主细胞的方法。此外，本发明还包括包含白蛋白融合蛋白的药物组合物，以及使用本发明白蛋白融合蛋白治疗、预防或改善疾病、失调或病症的方法。 融合蛋白可包括混合（人血清白蛋白）/Kex2前导序列，然后是与成熟干扰素α-2b的N端融合的成熟白蛋白。
• Fusion proteins of albumin and erythropoietin
  申请人：Human Genome Sciences, Inc.

  公开号：EP2277888A2

  公开（公告）日：2011-01-26

  The present invention encompasses albumin fusion proteins, namely fusions of human serum albumin and erythropoiethin. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

  本发明包括白蛋白融合蛋白，即人血清白蛋白和红细胞生成素的融合蛋白。本发明还包括编码本发明白蛋白融合蛋白的核酸分子、含有这些核酸的载体、用这些核酸载体转化的宿主细胞，以及制造本发明白蛋白融合蛋白和使用这些核酸、载体和/或宿主细胞的方法。此外，本发明还包括包含白蛋白融合蛋白的药物组合物，以及使用本发明白蛋白融合蛋白治疗、预防或改善疾病、失调或病症的方法。
• Fusion proteins of albumin and interferon beta
  申请人：Human Genome Sciences, Inc.

  公开号：EP2277889A2

  公开（公告）日：2011-01-26

  The present invention encompasses albumin fusion proteins, namely fusions of human serum albumin and interferon beta. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

  本发明包括白蛋白融合蛋白，即人血清白蛋白和干扰素β的融合蛋白。本发明还包括编码本发明白蛋白融合蛋白的核酸分子、含有这些核酸的载体、用这些核酸载体转化的宿主细胞，以及制造本发明白蛋白融合蛋白和使用这些核酸、载体和/或宿主细胞的方法。此外，本发明还包括包含白蛋白融合蛋白的药物组合物，以及使用本发明白蛋白融合蛋白治疗、预防或改善疾病、失调或病症的方法。
• ALBUMIN INSULIN FUSION PROTEIN
  申请人：Human Genome Sciences, Inc.

  公开号：EP2990417A1

  公开（公告）日：2016-03-02

  The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

  本发明包括白蛋白融合蛋白。本发明还包括编码本发明白蛋白融合蛋白的核酸分子、含有这些核酸的载体、用这些核酸载体转化的宿主细胞，以及制造本发明白蛋白融合蛋白和使用这些核酸、载体和/或宿主细胞的方法。此外，本发明还包括包含白蛋白融合蛋白的药物组合物，以及使用本发明白蛋白融合蛋白治疗、预防或改善疾病、失调或病症的方法。
• Ri-labeled humanized antibody
  申请人：NIHON MEDI-PHYSICS CO., LTD.

  公开号：US11369701B2

  公开（公告）日：2022-06-28

  The RI-labeled anti-MUC5AC humanized antibody of the present invention is a conjugate of a chelating agent chelated with a radionuclide and an antibody (the radionuclide is a metal nuclide that emits α particle or positron, and the antibody is a humanized antibody specifically binding to MUC5AC), and is superior in specificity for MUC5AC and accumulation in tumor. Therefore, it is extremely useful for the treatment and/or diagnosis of diseases in which MUC5AC is overexpressed, particularly cancer.

  本发明的RI标记抗MUC5AC人源化抗体是由螯合剂与放射性核素和抗体（放射性核素是发射α粒子或正电子的金属核素，抗体是特异性结合MUC5AC的人源化抗体）螯合而成的共轭物，对MUC5AC的特异性和在肿瘤中的蓄积性更强。因此，它对治疗和/或诊断 MUC5AC 过度表达的疾病，特别是癌症极为有用。